Abbreviated Dual Antiplatelet Therapy Followed by P2Y12 Inhibitor Monotherapy versus 12 Months' Dual Antiplatelet Therapy Post Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Ashish K UmeshMariam ShariffRajkumar DoshiIgor Pedreira VazPublished in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2021)
Abbreviated DAPT followed by P2Y12 monotherapy resulted in a similar risk of re-ischemic clinical outcomes post percutaneous coronary intervention as compared with the standard 12-month DAPT regimen. The risk of major bleeding (BARC type 3 or 5) also remained similar between the two groups. However, as trials have reported benefits with abbreviated DAPT followed by P2Y12 monotherapy in terms of combined endpoints and all bleeding (BARC type 2-5), additional research is needed.
Keyphrases
- antiplatelet therapy
- percutaneous coronary intervention
- acute coronary syndrome
- st segment elevation myocardial infarction
- atrial fibrillation
- combination therapy
- st elevation myocardial infarction
- acute myocardial infarction
- coronary artery disease
- coronary artery bypass grafting
- open label
- coronary artery bypass
- systematic review
- ischemia reperfusion injury
- randomized controlled trial
- study protocol
- left ventricular